Abstract
Background: Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. Methods: We assessed the clinical outcomes of breakthrough COVID-19 in fully vaccinated individuals. Results: In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID- 19, there were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated with the number of medical comorbidities. Antispike monoclonal antibody treatment was significantly associated with a lower risk of hospitalization (odds ratio, 0.227; 95% confidence interval, 0.128-0.403; P <. 001). The number needed to treat (NNT) to prevent 1 hospitalization was 225 among the lowest risk patient group compared with NNT of 4 among those with highest numbers of medical comorbidity. Conclusions: Monoclonal antibody treatment is associated with reduced hospitalization in vaccinated high-risk persons with mild to moderate COVID-19.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 598-602 |
| Number of pages | 5 |
| Journal | Journal of Infectious Diseases |
| Volume | 225 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 15 2022 |
Keywords
- Breakthrough COVID-19
- Casirivimab-imdevimab
- Hospitalization
- SARS-CoV-2
- Vaccination
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases